NO-aspirins: Antithrombotic activity of derivatives of acetyl salicylic acid releasing nitric oxide

Cardiovascular Drug Reviews

Volumn 16, Issue 1, 1998, Pages 31-47

  Minuz, Pietro ^a,b   Lechi, Clara ^a   Zuliani, Valeria ^a   Gaino, Stefania ^a   Tommasoli, Rosamaria ^a   Lechi, Alessandro ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b POLICLINICO BORGO ROMA   (Italy)

Author keywords

Gastric ulcers; NCX 4016; NCX 4215; NO aspirin; Platelet adhesion; Platelet aggregation; Vasorelaxation

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; CALCIUM ION; CYCLIC GMP; DICLOFENAC; FLURBIPROFEN; METHYLENE BLUE; NITRIC OXIDE; OXYHEMOGLOBIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CALCIUM CELL LEVEL; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 0031874813     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1998.tb00343.x     Document Type: Article

References (49)

1. Adami A, Cuzzolin L, Minuz P, Crivellente F, Lechi A, Benoni G. Vasodilating properties of a new non-steroidal antiinflammatory drug, nitroflurbiprofen on rat aortic rings. Pharmacol Res 1996;33:139-144.
2. Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC. Nitric oxide and nitrovasodilators: Similarities, differences and potential interactions. J Am Coll Cardiol 1994;24:555-566.
3. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
4. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann NY Acad Sci 1993;677:293-308.
5. Bellavite P, Andrioli G, Guzzo P, et al. Colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994;216:444-450.
6. Brown JF, Eats AC, Hanson PJ, Wittle BRJ. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric microcirculation. Eur J Pharmacol 1989;174:293-296.
7. Buechler WA, Ivanova K, Wolfram G, Drummer C, Heim JM, Gerzer R. Soluble guanylyl cyclase and platelet function. Ann NY Acad Sci 1994;714:151-157.
8. Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994;72:1-15.
9. Cherry PD, Omar HA, Farrell KA, Stuart JS and Wolin MS. Superoxide anion inhibits cGMP-associated bovine pulmonary arterial relaxation. Am J Physiol 1990;259:H1056-H1062.
10. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does affect the flow cytometry detection of fibrinogen binding to, or release of α-granules or lysosomes from, human platelets. Clin Sci 1994;87:575-580.
11. Cirino G, Cicala C, Mancuso F, Baydoun AR, Wallace JL. Flurbinitroxybutylester: A novel antiinflammatory drug has enhanced antithrombotic activity. Thromb Res 1995;79:73-81.
12. 2 production in rats. Life Sci 1996;58:207-210.
13. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal and-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995;109:524-530.
14. 2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B-15B
15. Gerzer R, Karrenbrock W, Siess W, Heim JM. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate-cyclase activity. Thromb Res 1988;52:11-21.
16. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992;4:766-771.
17. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
18. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-869.
19. 2 production. Thromb Haemost 1996;76:791-798.
20. Lechi C, Gaino S, Tommasoli R, et al. In vitro study of the anti-aggregating activity of two nitroderivatives of acetyl-salicylic acid. Blood Coag Fibrinolysis 1996;7:206-209.
21. Lopez-Belmonte J, Wittle BRJ, Moncada S. The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 1993;108:73-78.
22. MacNaughton WK, Cirino G, Wallace JL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 1989;45:1869-1876.
23. Mariotto S, Cuzzolin L, Adami A, Del Soldato P, Suzuki H, Benoni G. Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of the inducible nitric oxide synthase in rat neutrophils. Br J Pharmacol 1995;115:225-226.
24. Meade EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268: 6610-6614.
25. Minuz P, Lechi C, Bonapace S, et al. Effects of a new class of NO-releasing NSAIDs on platelets and isolated arteries. Inflammopharmacology 1996;4:83-90.
26. Minuz P, Lechi C, Tommasoli R, et al. Anti-aggregating and vaso-dilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb Res 1995;80:367-376.
27. Moro MA, Russel RJ, Cellek S, et al. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996;93:1480-1485.
28. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372
29. 2 production in healthy subjects. Thromb Res 1980;17:317-327.
30. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
31. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-3076.
32. Salvemini D, Pistelli A, Vane J. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells. Br J Pharmacol 1993;108:162-169.
33. Santini G, Sciulli MG, Panara MR, et al. Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases. Eur J Pharmacol 1996;316:65-72.
34. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263:181F-191F.
35. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related compounds in vitro and in vivo and their relevance to cardiovascular disorder. J Am Coll Cardiol 1991;18:529-53.
36. Stenberg PE, Mc Ever RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886.
37. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
38. Ukawa H, Hirata T, Kobayashi H, Yamakuni H, Takeuchi K. Effects of COX-2-selective and NO-releasing NSAIDS on mucosal ulcerogenic and healing responses in rat stomach. Gastroenterology 1997;112:A317.
39. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994;15:405-406.
40. Wallace JL, Cirino G, McKnight W, Elliott SN. Reduction of gastrointestinal injury in endotoxic shock by flurbiprofen nitroxybutylester. Eur J Pharmacol 1995;280:63-68.
41. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995;96:2711-2718.
42. Wallace JL, McKnight W, Tammy L, Wilson TL, Del Soldato P, Cirino G. Gastric protection from hemorrhagic shock-induced damage by nitric oxide-releasing aspirin derivative (NCX 4016). Gastroenterology 1997;112:A417.
43. Wallace JL, McKnight W, Tammy L, Wilson TL, Del Soldato, P, Cirino G. Reduction of shock-induced gastric damage by a nitric-releasing aspirin derivative: Role of neutrophils. Am J Physiol 1997;273:G1246-G1251.
44. Wallace JL, McKnight W, Wilson TL, Cirino G, Del Soldato P, Davies NM. Nitric oxide-releasing aspirin derivative (NCX 4016): A gastrin-sparing antithrombotic drug. Gastroenterology 1997;112:A325.
45. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173-179.
46. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994;257:249-255.
47. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997;112:1000-1016.
48. Whittle BJR. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: Integrity of the balance. Br J Pharmacol 1993;110:3-17.
49. Whittle BRJ. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981;80: 94-98.